Hypotension
Conditions
Brief summary
One in ten patients on rivaroxaban therapy have dizziness and reductions in blood pressure. The investigators intend to monitor the ambulatory blood pressure of such patients in order to assess whether this is a true haemodynamic effect.
Interventions
Patients with dizziness on taking rivaroxaban will have ambulatory blood pressure monitoring to assess haemodynamic effects indirectly
Sponsors
King's College Hospital NHS Trust
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Aged 18-75 years * Able to provide written, informed consent * Taking rivaroxaban for any indication within the license of the drug, both once daily and twice daily dosing can be included * Have measurable rivaroxaban levels on at least one occasion (this will be in line with standard of care, there will be no extra blood samples for the study) * Not taking concomitant medication that can affect rivaroxaban metabolism (including amiodarone, dronedarone, -azole antifungals, protease inhibitors) * On no antihypertensive or vasoactive medication * Have a baseline BP recording taken in clinic
Exclusion criteria
* Unable to provide written, informed consent * Presence of concomitant medication that may alter rivaroxaban levels and confound results (see above) * Unwilling to undergo ambulatory blood pressure monitoring * Contraindication to ambulatory blood pressure monitoring
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Average blood pressure readings | 48 hours |
Secondary
| Measure | Time frame |
|---|---|
| Correlation of blood pressure readings to rivaroxaban dosing | 48 hours |
| Correlation of blood pressure readings to symptomatology | 48 hours |
Countries
United Kingdom
Outcome results
None listed